SKL35501 / Full-Life Technologies Limited, SK Bio - LARVOL DELTA

Preclinical development of FL-091, a novel NTSR1 targeting radionuclide drug conjugate for the treatment of NTSR1-positive cancers (EANM 2024) - "NTSR1 was highly expressed across multiple types of cancers, especially in head and neck and colorectal cancer. These data, along with the encouraging anti-tumor activity observed across in vivo models, suggest that 177Lu-FL-091 is a promising RDC candidate for the treatment of NTSR1-positive cancers. Studies to investigate FL-091 conjugated to the radionuclide Actinium-225 are in progress."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • FOLH1

Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors (PRNewswire) - "Full-Life Technologies...announced today that it has entered into a license agreement with SK Biopharmaceuticals, a global biotech company, for exclusive worldwide clinical research, development, manufacturing, and commercialization rights to Full-Life's 'FL-091' radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) positive cancers. This licensing deal worth $571.5 million includes an upfront payment, and development and commercial milestones, separate from royalties. Under the terms of the agreement, SK Biopharmaceuticals will in-license the NTSR1-targeting Radionuclide Drug Conjugate (RDC) program FL-091 - as well as its back-up compounds - aimed at developing and commercializing it as an innovative anti-cancer drug....SK Biopharmaceuticals also has a right of first negotiation to license other pre-selected RDC programs of Full-Life."

Licensing / partnership • Solid Tumor

Development of 177Lu-FL-091 for the treatment of NTSR1-positive cancers (SNMMI 2024) - "In PC-3 xenograft model that was negative for AR or PSMA expression, single dose of 177Lu-FL-091 at 37 MBq induced >30% tumor shrinkage in all treated mice (Figure E). NTSR1 was found to be highly expressed across multiple types of cancers, especially in head and neck and colorectal cancer. FL-091 displayed enhanced binding affinity to NTST1 and antagonist activity compared to 3BP-227. In addition, 177Lu-FL-091 demonstrated improved in vivo biodistribution profile vs."

Colorectal Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Genito-urinary Cancer • Head and Neck Cancer • Hepatology • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor • FOLH1

Full-Life Technologies Acquires Focus-X Therapeutics (WCG’s FDAnews) - "Full-Life Technologies...has entered into an agreement to acquire Focus-X Therapeutics and its cancer-targeting radiopharmaceuticals....Under the terms of the acquisition, Full-Life will gain Focus-X’s two investigational lead compounds. The first is a prostate specific membrane antigen-targeted peptide for the treatment of metastatic castration resistant prostate cancer. The second is a neurotensin receptor type 1 (NTSR1)-targeted peptide for the treatment of pancreatic cancer....Full-Life will also be acquiring Focus-X’s six other programs that are in earlier stages of development...Under the terms of the acquisition, Focus-X shareholders are eligible to receive an upfront payment along with potential development, regulatory and sales-based milestone payments of up to $245 million. The acquisition is expected to close in the first quarter of 2023."

M&A • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor